peptide pulsed dendritic cell

Peptide pulsed dendritic cells are a form of personalized cellular immunotherapy in which autologous or allogeneic dendritic cells (DCs) are loaded ex vivo with specific synthetic peptides derived from tumor antigens or neoantigens. These "pulsed" DCs present the selected peptides via major histocompatibility complex (MHC) molecules to T cells upon administration to the patient. The goal is to induce a robust and antigen-specific cytotoxic T lymphocyte (CTL) response against cancer cells expressing those antigens. This approach has been studied for various solid tumors and hematologic malignancies, including pancreatic cancer and melanoma. The therapy is typically administered as a vaccine after surgical resection or in advanced disease settings and may be combined with other immunotherapies such as CTLs generated ex vivo[1][2][3][4][5][7][8].

Other names

peptide-pulsed dendritic cellpeptide-pulsed DCantigen-pulsed dendritic celltumor-associated peptide antigen-pulsed dendritic cell vaccineneoantigen peptide-pulsed dendritic cell vaccine